[Asuka Pharmaceutical] Share Buyback and Revision of Executive Compensation System | July 2026

Details and Purpose of Disposal

Asuka Pharmaceutical resolved on August 12, 2026, to dispose of 53,600 common shares at 2,259 yen per share. This disposal is part of a long-term incentive granted to directors based on a restricted stock compensation plan, aimed at enhancing shareholder value and motivating executives. The funds obtained from the disposal are planned to be used for partial revision of the executive compensation system and to promote long-term shareholder value sharing.

Revision of Executive Compensation System and Long-Term Incentives

Asuka Pharmaceutical has partially revised its restricted stock compensation plan for directors by introducing a new scheme that grants shares over a long period to designated directors. The revision aims to increase the linkage between compensation and performance, setting the restricted period up to 50 years to foster long-term corporate value enhancement. This approach seeks to strengthen directors’ commitment to corporate value and promote value sharing with shareholders.